TABLE 3.
Comparison of the baseline data of hypertension patients with ischemic stroke between the testing group and validation group
| Variables | Hypertension with ischemic stroke (testing group) | Hypertension with ischemic stroke (validation group) | χ 2/t | P |
|---|---|---|---|---|
| Number of patients | 92 | 108 | ||
| Age, (mean ±SD) | 53.8 ± 6.2 | 53.7 ± 6.6 | 0.110 | 0.913 |
| Male (%) | 48 (52.2) | 55 (50.9) | 0.031 | 0.860 |
| Body mass index (mean ±SD, kg/m2) | 23.5 ± 1.7 | 23.4 ± 1.3 | 0.471 | 0.638 |
| Diabetes (%) | 13 (14.1) | 11 (10.2) | 0.732 | 0.392 |
| Smoking (%) | 6 (6.5) | 10 (9.3) | 0.506 | 0.477 |
| Drinking (%) | 25 (27.2) | 30 (27.8) | 0.009 | 0.924 |
| CTLA‐4 concentrations (mean ±SD, ng/mL) | 5.3 ± 1.6 | 5.5 ± 1.8 | −0.824 | 0.411 |
| Lp‐PLA2 concentrations (mean ±SD, ng/mL) | 27.5 ± 7.3 | 27.1 ± 6.5 | 0.410 | 0.682 |
| HCY concentrations (mean ±SD, nmol/L) | 61.1 ± 8.8 | 60.8 ± 9.6 | 0.229 | 0.819 |
| MIP concentrations (mean ±SD, pg/mL) | 102.9 ± 21.5 | 104.3 ± 20.1 | −0.475 | 0.635 |
| IMA concentrations (mean ±SD, pg/mL) | 1.9 ± 0.6 | 2.0 ± 0.4 | −1.404 | 0.162 |
| GFAP concentrations (mean ±SD, mg/L) | 105.5 ± 24.1 | 106.2 ± 21.9 | −0.215 | 0.830 |
| IL−2 concentrations (mean ±SD, pg/mL) | 112.4 ± 28.5 | 111.8 ± 27.0 | 0.153 | 0.879 |
| IL−1α concentrations (mean ±SD, pg/mL) | 69.7 ± 14.7 | 69.4 ± 13.7 | 0.149 | 0.882 |
Abbreviation: CTLA‐4, cytotoxic T lymphocyte‐associated antigen‐4; IMA, ischemia‐modified albumin; IL‐1α, interleukin‐1 alpha; IL‐2, interleukin‐2; MIP, macrophage inflammatory protein; HCY, homocysteine; Lp‐PLA2, lipoprotein‐associated phospholipase A2; GFAP, glial fibrillary acidic protein.